SCHEMBL14133394

SCHEMBL14133394

CS(=O)(=O)Nc1ccc(C2=NN(C(=O)CCC(=O)O)C(c3cccc(F)c3)C2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.68
▸ ALDH1A1 P00352 7/20 0.68
▸ PKM P14618 5/20 0.68
▸ KMT2A Q03164 3/20 0.61
▸ RAB9A P51151 2/20 0.60
▸ ITGB3 P05106 1/20 0.60
▸ ITGAV P06756 1/20 0.60
▸ MAPT P10636 2/20 0.59
▸ GLA P06280 2/20 0.58
▸ HTT P42858 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ HPGD P15428 3/20 0.58
▸ GAA P10253 1/20 0.58
▸ MEN1 O00255 2/20 0.57
▸ BCL2 P10415 2/20 0.56
▸ BECN1 Q14457 2/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ POLB P06746 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14133973 0.95 KMT2A (0.69) KDM4EALDH1A1PKMKMT2ARAB9A
SCHEMBL14133805 0.90 KDM4E (0.71) KDM4EALDH1A1PKMKMT2ARAB9A
SCHEMBL14132768 0.90 KDM4E (0.71) KDM4EALDH1A1PKMKMT2ARAB9A
SCHEMBL14133987 0.89 KDM4E (0.67) KDM4EALDH1A1PKMKMT2ARAB9A
SCHEMBL14133881 0.88 KMT2A (0.59) KDM4EALDH1A1PKMKMT2ARAB9A
SCHEMBL14133395 0.87 ALDH1A1 (0.74) KDM4EALDH1A1PKMKMT2AMAPT
SCHEMBL14133320 0.84 KDM4E (0.71) KDM4EALDH1A1PKMKMT2ARAB9A
SCHEMBL14133441 0.84 KDM4E (0.71) KDM4EALDH1A1PKMKMT2ARAB9A
SCHEMBL14133370 0.84 KMT2A (0.77) KDM4EALDH1A1PKMKMT2ARAB9A
SCHEMBL14133876 0.84 KDM4E (0.80) KDM4EALDH1A1PKMKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 KDM4E 376/4885ALDH1A1 2476/4885PKM 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback